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Abbreviations
AD Alzheimer’s disease
AMPA -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
ATP/ADP Adenosine tri/di phosphate
BBB Blood brain barrier
CSF Cerebrospinal fluid
CNS Central nervous system
ECF Extracellular fluid
ER Endoplasmic reticulum
MAPK Mitogen activated protein kinase
MT Metallothionein
RDA Recommended daily allowance
UIL Upper intake level
VGCC Voltage-gated Ca2+ channels
(S)VZ (Sub)Ventricular zone
ZIP Zn2+ importing proteins
[Zn] Concentration of Zn
ZnT Zn transporter
149.1  Introduction
The physiological importance of zinc (Zn) was first recognized in 1940 when the Zn-containing 
enzyme, carbonic anhydrase, was described (Keilin and Mann 1940). Eventually, Zn was recognized 
as an ‘essential’ trace element found widely distributed in all human organs and tissues and required 
for the structure and functions of many cellular proteins (Table 149.1). Today, the importance of Zn 
in human health is well documented (Frederickson et al. 2005; Maret and Sandstead 2008). In the 
brain, Zn plays important roles both in its development and function.
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Zinc metalloproteins are the major (~80%) reservoir of the total brain Zn while the rest is free 
Zn2+ and are histochemically detectable by Timm’s sulfide-silver staining method (Frederickson and 
Danscher 1990). In the brain, Zn is relatively concentrated in the hippocampus and amygdala (Takeda 
et al. 2004). Both regions are enriched with histochemically reactive Zn2+ which predominantly 
exists in the presynaptic vesicles. Zinc homeostasis in the brain is maintained by the blood brain 
barrier system and is not easily disrupted by dietary Zn deficiency. Nevertheless, histochemically 
detectable Zn in hippocampus are susceptible to dietary Zn deficiency.
Most of the cells in the human body including neuron maintain Zn homeostasis through the regu-
lated expression of proteins for Zn- import, export, and sequestration. Specific Zn transporters are 
used in certain tissues and their expression may vary with dietary Zn status and time (Dufner-Beattie 
et al. 2003; Kelleher and Lonnerdal 2003). Thus Zn homeostatic mechanisms appear to be tissue 
specific.The mechanism of exact regulation of Zn uptake from extracellular fluids (ECF) into neu-
rons and glial cells, however, is not completely known.
Large numbers of the world’s population, an estimated total of about 50%, are at risk of Zn defi-
ciency (Brown et al. 2001). Zinc deficiency in children is a nutritional and health concern in both 
developing and developed countries (Black 1998; Bryan et al. 2004). Zinc deficiency results in 
decrease in extracellular [Zn] in the hippocampus which subsequently causes abnormal glucocorti-
coid secretion from the adrenal cortex. As the hippocampus is enriched with glucocorticoid recep-
tors, the abnormal glucocorticoid secretion alters its function. Abnormal glucocorticoid secretion in 
Zn deficiency is associated with neuropsychological symptoms affecting cognitive performance and 
aggravated glutamate excitotoxicity. The decrease in Zn2+ pool in the peripheral tissue in Zn defi-
ciency can also change glucocorticoid action by triggering abnormal glucocorticoid secretion.
Table 149.1 Key facts on zinc
Chemistry and physical properties
  Discovery: German chemist Andreas Sigismund Marggraf (1746) is normally given credit for discovering pure 
metallic Zn.
 Avaialability: the 24th most abundant element on the Earth’s crust
 Empirical formula: Zn
 Position in the periodic table: 1st element in group 12
 Number of stable isotopes: five
 Atomic number: 30
 Atomic weight: 65.39 g
Uses
 Zinc plating for corrosion-resistance (e.g. on steel).
 Zinc alloys such as brass (alloy of zinc and copper) is used in batteries.
 Zinc chloride in deodorants
 Zinc pyrithione in shampoos
 Zinc sulfide in luminescent paints
 Zinc-carbonate, Zn-gluconate as dietary supplements
Biological importance
 Considered an essential mineral
  Structural component of many enzymes such as alcohol dehydrogenase in humans or other biomolecules 
important in cellular and molecular processes such as Zn finger transcription factors.
  Half of the total body’s Zn is present in muscle. Other major organs of the body that contain zn includes bones, 
skin, kidneys, testes, and prostate glands
 Zinc deficiency causes growth retardation, delayed sexual maturation, infection susceptibility, and diarrhea, etc.
 Zinc excess is associated with ataxia, lethargy, and copper and iron deficiency.
This table includes the key facts on Zn including its chemical properties, uses, and biological importance
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Alterations in Zn homeostasis in the brain is observed in Parkinson’s and Alzheimer’s disease 
(AD) as well as in transient forebrain ischemia, seizures, and traumatic brain injury. There is much 
evidence to show that amyloid-beta deposition in AD is induced by Zn (see review Mocchegiani 
et al. 2005). An elevated concentration of Zn or an excess of Zn in the brain might play a role in such 
pathological conditions. Indeed the exact neuropathological mechanism of either the elevated level 
of Zn2+ or its deficiency has not been completely resolved (Colvin et al. 2003; Sensi et al. 2009).
This chapter will elaborate on the physiological importance of dietary Zn in the brain. Emphasis 
will be given to the mechanism of Zn homeostasis, the role of dietary Zn in brain development, and 
the consequences of Zn excess and/or Zn deficiency in brain pathology.
149.2  Dietary Sources of Zn and Its Bioavailability
The richest food sources of Zn (Table 149.2) are sea foods (shellfish, shrimp, lobster, crab-meat), organs 
and flesh of mammals and fowls (liver, meat), whole grain cereals, and some beans (Brown and Begin 
1993). The total Zn content of the diet and its bioavailability, solubility in particular, in the intestinal lumen 
determines the amount of Zn absorbed and which can be utilized or metabolized in different organs. This 
also is influenced by the chemical form of Zn and the presence or absence of specific enhancers or inhibi-
tors of Zn absorption. Amino acids such as cysteine and histidine can increase the solubility of Zn. 
However, some proteins such as casein have an inhibitory effect on Zn absorption. Myoinositol hexaphos-
phate (phytate) reduces Zn bioavailability (Soto-Quintana et al. 2003), and therefore oils, fats, and sugar 
are not considered good sources of Zn. Meal proteins have a positive effect on Zn absorption. In humans 
without excessive intake of Zn, the body burden half-time of absorbed Zn has been observed in the range 
between 162–500 days. After parenteral administration, half-times of Zn may vary within the range of 
about 100–500 days (see review Lowe et al. 2009). In spite of its great importance in human health, the 
amount of zinc in the diet, however, needs to be maintained properly (Table 149.3).
149.3  Blood Brain Barrier and Permeability of Zn in Brain
Both the supply of the required nutrients for proper functioning of the brain and the control of harm-
ful substances present in the bloodstream so as to prevent them from entering the brain are done by 
the specialized system of capillary endothelial cells of the blood brain barrier (BBB). The transport 
Table 149.2 Zinc in human diet (From Brown and Begin 1993)
Category of foods Example of edibles
Major dietary source of Zn
 Sea foods flesh of shellfish, shrimp, lobster, crab
 Organs and flesh of mammals and fowls liver, meat, or muscle
 Whole grain cereals, vegetables chickpeas, kidney beans, almonds
 Dairy products yogurt, milk, cheese
Inhibitors of Zn absorption Casein
 Protein Plant oil
 Oils or fats Sugar
 Carbohydrate
Zinc is available in various food and food products. This table includes a partial list of the dietary 
sources of Zn. The amount of Zn, however, may vary depending on type and species
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of Zn into the brain parenchyma occurs via the BBB system (Kahn 2005). Entry of Zn into the brain 
is allowed through different kinds of proteins and channels on the BBB (Fig. 149.1). In other words 
the BBB system provides a strict regulation on Zn homeostasis in the brain and is not easily dis-
rupted by dietary Zn (Franklin et al. 1992).
The presence of specific Zn transport sites on the brain capillary endothelial cells (Buxani-Rice 
et al. 1994) confirms the important regulatory role of the BBB in brain Zn homeostasis. The BBB-
mediated control of Zn homeostasis in the brain is also supported by the enhanced transport of Zn 
across the BBB, as shown by an in vitro model of the BBB that was exposed to Zn-deficient conditions. 
The rate of Zn transport across the in vitro BBB model constructed using cultured porcine brain 
Fig. 149.1 The blood-brain barrier controls the exchange of ions including zinc, amino acids, peptides, and other 
substances between blood and brain. At the brain blood capillaries, the endothelium cells (i) are joined together at their 
edges by tight junctions (ii),which prevent water-soluble substances in the blood to enter the CSF. Most of the areas of 
the blood capillaries are enclosed by the astrocyte’s “end-feet” (iii). Thus water-soluble substances can cross the BBB 





, anesthetics and alcohol can pass straight through the lipids in the capillary walls (iv). Ions 
and amino acids can pass through using carrier proteins such as zinc import proteins (v), ion channels or pumps (vi) 
(Modified from Springer Image library accessed on 01 January, 2010 from http://www.springerimages.com/Images/
Pharmacy/1-10.1208_s12248-008-9018-7-0)
Table 149.3 Recommended daily allowance (RDA) and upper intake levels (UIL) for human Zn consumption (From 
Institute of Medicine, Food and Nutrition Board. Washington, DC: National Academy Press, 2001)
Age
For male For female In pregnancy During lactation
RDA/UIL RDA/UIL RDA/UIL RDA/UIL
0–6 months 2 mg/4 mg 2 mg/4 mg   
7–12 months 3 mg/5 mg 3 mg/5 mg   
1–3 years 3 mg/7 mg 3 mg/7 mg   
4–8 years 5 mg/12 mg 5 mg/12 mg   
9–13 years 8 mg/23 mg 8 mg/23 mg   
14-18 years 11 mg/34 mg 9 mg/34 mg 13 mg/34 mg 14 mg/34 mg
19+ years 11 mg/40 mg 8 mg/40 mg 11 mg/40 mg 12 mg/40 mg
Both the recommended amount of dietary Zn or Zn supplement and upper tolerable levels vary depending on age, 
gender, or stage of growth and development. This table includes the amount of Zn recommended for daily consump-
tion and the maximum or upper tolerable limit (UIL) for different ages or conditions to maintain optimum health
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capillary endothelial cells on porous membrane was observed to be slower when [Zn] was below 
7 mol/L and faster when it was above 30 mol zinc/L (Lehmann et al. 2002). Notably, the zinc 
transport process is highly selective for Zn since none of the analogous minerals could effectively 
compete with zinc; besides, the zinc transfer process does not require much energy. Furthermore, 
metabolic inhibitors also do not influence the transport rate (Bobilya et al. 2008).
In order to maintain Zn homeostasis, brain capillary endothelial cells respond to changes in Zn 
status, increasing the uptake of Zn in the presence of low [Zn] in the blood and decreasing it in the 
presence of high [Zn] in the blood (Lehmann et al. 2002). Following its uptake, Zn can be transferred 
freely through the CSF and the brain ECF compartments. The reduced amount of histochemically 
reactive Zn in Zn deficiency suggests its reduced uptake in Zn deficiency (Takeda 2001).
149.4  Homeostasis of Zn in the Brain and Dietary Influence
The variation in the amount of Zn in different regions of the mammalian central nervous system 
(CNS) varies over about a fivefold range, with lower amounts generally in white matter (26–40 ppm 
in cortical white matter) and higher amounts in grey matter (60–90 ppm in cortical grey matter). On 
an average, the estimated amount of Zn in one gram of wet brain tissue is about 10 g corresponding 
to an average total intracellular [Zn] of about 150 M. This concentration is about 10-fold more than 
the serum [Zn]. On the regional distribution within the brain, the estimated total [Zn] in the hip-
pocampus is more than 200 M (see review Takeda and Tamano 2009), considered the highest com-
pared to any other region (Frederickson et al. 2005). Notably, hippocampal [Zn] can be decreased 
significantly in dietary Zn deficiency. Among the other regions, the amygdala and neocortex contain 
the highest amount of Zn (Fig. 149.2).
In the ECF of the brain, Zn is either bound to low molecular weight ligands such as metalloproteins, 
or stay as free Zn2+ (see review Takeda and Tamano 2009). In the ECF, the estimated total [Zn] and 
Fig. 149.2 Human brain-zinc map. The hippocampus belongs to the limbic system containing the highest concentra-
tion of zinc in the brain (dark black area). Other regions of the brain that contain relatively higher amount of Zn is the 
amygdala (dark black area) and grey matter neocortex (black dotted area)
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free [Zn2+] are 0.15–1 M (Hershey et al. 1983; Weiss et al. 2000) and ~5–20 M (Frederickson et al. 
2006) respectively. About 80% of the total brain Zn is bound with Zn metalloproteins while the rest 
is histochemically detectable using Timm’s sulfide-silver staining method (Frederickson and 
Danscher 1990). This is based on the observation that the removal of Zn transporter protein results 
in a 20% reduction of the total amount of Zn in the brain (Cole et al. 1999).
Within the brain, both the extracellualr and intracellular Zn are exchangeble. Extracellular Zn2+ in 
the brain may change because of its release from cells (Frederickson 1989; Qian and Noebels 2005), 
while changes in intracellular Zn2+ may result from oxidative stress (Frazzini et al. 2006). The con-
centration of rapidly exchangeable cytosolic free Zn2+ is estimated in the subnanomolar level. Such 
dynamic changes in Zn2+ gradients and the availability of specific Zn2+ binding domains suggest the 
importance of Zn2+ ions as signaling molecules. However, the signaling effects of Zn2+ may be medi-
ated by intracellular or extracellular Zn2+ (Sensi et al. 1997).
In Zn deficiency, the level of serum Zn decreases which in turn leads to a decrease in CSF Zn. 
Although one week of Zn deprivation in young rats can decrease serum Zn level about 50% com-
pared to control animals, a significant change (decrease) in extracellular Zn in the hippocampus is 
observed only after 4 weeks of Zn deprivation. Histochemically reactive Zn (Timm’s stain) also 
decreases after 4 weeks of Zn deprivation. Thus only a prolonged period of Zn deficiency (4 weeks 
in contrast to 1 week) can cause a decrease in hippocampal Zn. Notably, extracellular Zn may lead 
to the decrease in histochemically reactive Zn. Extracellular Zn is also responsive to dietary Zn defi-
ciency in other regions such as the amygdala, followed by a decrease in histochemically reactive Zn 
(Takeda and Tamano 2009).
The protein-bound Zn in intracellular compartments of the brain, on the other hand, may be resistant 
to Zn deficiency. It is possible that the response of hippocampal Zn to dietary Zn deficiency reflects that 
of peripheral Zn since the decrease in serum Zn may lead to the reduction of Zn2+ pool in peripheral 
tissues. It is possible that insufficient Zn2+ signaling in peripheral tissues is associated with activation 
of the hypothalamo-pituitary-adrenocortical system in Zn deficiency (Takeda and Tamano 2009).
149.5  Transport and Homeostasis of Zn in Neuron and Dietary Influence
Cells in different parts of the brain have different amounts of Zn which in turn contributes to the 
variable amount of Zn in different brain areas. The free [Zn2+] in the cytosol from cultured neurons 
is estimated at subnanomolar (Weiss et al. 2000). However, Zn content in the synaptic vesicles of 
some neurons in the forebrain is found to be approximately >1 mM (Frederickson et al. 2005). 
Although intraneuronal cytosolic Zn2+ is in the subnanomolar or picomolar range, it is estimated to 
rise to micromolar levels in the proximity of axon terminals following release from synaptic vesicles 
that contain Zn2+ at millimolar range (Frederickson et al. 2005). This is most likely also the case in 
other intracellular compartments such as mitochondria, vesicles, and lysosomes that can take up 
cytosolic Zn2+ (Sensi et al. 2003; Colvin et al. 2006; Hwang et al. 2008; Dittmer et al. 2009).
Neurons that contain free Zn2+ in the vesicles of their presynaptic boutons are present both in 
forebrain areas (such as hippocampus, amygdala, and neocortex) and other areas of the brain 
(Fig. 149.2). Those neurons in the forebrain area are a subgroup of excitatory glutamatergic (or 
gluzinergic) neurons and in other areas they are termed Zn-enriched neurons (Frederickson and 
Danscher et al. 1990). Since the distribution of these neurons within the brain is not uniform, Zn 
distribution in the brain is also not uniform.
The exact mechanism that regulates Zn uptake from the ECF into neurons and glial cells is still 
not completely known. Most of the cells maintain Zn homeostasis through the regulated expres-
sion of proteins for Zn import, export, and sequestration (Table 149.4). Furthermore, Zn homeostatic 
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mechanisms appear to be tissue specific. Specific Zn transporters are used in certain tissues and its 
expression varies with dietary Zn status and time (Dufner-Beattie et al. 2003; Kelleher and 
Lonnerdal 2003). A number of Zn2+ transporters (ZnTs), Zn2+-importing proteins (ZIPs), and buff-
ering proteins such as the metallothioneins (MT) bind cytosolic Zn2+ and mediate the complex 
intraneuronal cytosolic Zn2+ homeostasis. In addition, specific gated Zn-permeable membrane-
spanning channels, such as voltage-gated L-type Ca2+ channels, Na+/Zn2+ exchangers, N-methyl-
D-aspartate (NMDA) receptor gated channels, and Ca2+ permeable AMPA/kainate channels can 
also mediate the neuronal uptake of Zn. Zinc transporter proteins too regulate the efflux of Zn 
from neurons as well as vesicular Zn uptake. Transporters of the Zip family, which are the main 
membrane Zn uptake transporters, also seem to be involved in this process (reviewed in Ohana 
et al. 2009).
ZnTs mediate Zn2+ transport from the cytosol to the lumen of intracellular organelles or out of the 
cell. There are at least ten members of the ZnT family, most of which are ubiquitously expressed, 
except ZnT3 which is neuron specific and present on synaptic glutamatergic vesicles. With the 
exception of ZnT1, ZnTs are present on intracellular organelles such as the Golgi and the secretory 
vesicles of many organs (Table 149.4). Zinc Transporter 1 is expressed, synaptically and extrasynap-
tically, on the plasma membrane of neurons and glia. Other ZnT family members, ZnT2, ZnT4, 
ZnT5, and ZnT6, are also expressed in several brain regions (reviewed in Sensi et al. 2009) such as 
in the hippocampus, cortex, and olfactory bulb (Lee et al. 2003), and in certain cerebellar GABAergic 
and dopaminergic neurons (Ruiz et al. 2004). Zin Transporter 7, which probably facilitates Zn2+ 
transport from the cytoplasm into the Golgi apparatus, is moderately expressed in the brain and 
ZnT2, ZnT5, and ZnT6, which are associated with vesicular Zn uptake and Zn efflux in many organs, 
should similarly play a minor role in the brain.
149.6  Biochemistry of Zn Binding with Proteins in Brain
The knowledge of the biochemical importance of Zn dates back to 1940 with the discovery of the 
Zn-containing enzyme, carbonic anhydrase, now known to contain 1 gram atom of the metal per 
mole (Keilin and Mann1940). Subsequently, more than 300 such Zn containing proteins with catalytic, 
Table 149.4 Zn2+ transport and storage in neurons
Zn transporter(s) or storage protein Important features
VGCCs and Ca2+/Zn2+-permeable AMPA  
receptors
Located at the plasma membrane the main routes Zn2+ entry into 
neurons
ZnT1 Located at the plasma membrane controls Zn2+ efflux interacts with 
the L-type VGCC that regulates Ca2+ and Zn2+ influx.
ZnT3 Located at the synaptic vesicles
ZnT5, ZnT6, ZnT7 Located at the golgi apparatus
ZnT5, ZnT6, ZnT7 Located at the lysozome
The Nas/Zn2+ exchanger Moves Zn2+ in or out of neurons depending on the Na+ gradient
ZIP H+- or HCO
3
-Zn2+ co-transporters and facilitates Zn2+ influx.
Ca2+ uniporter Located at mitochondria
MT (MT-III) Major Zn2+-homeostatic proteins in neurons
AMPA, -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; MT, metallothionein VGCCs, voltage-gated Ca2+ 
channels; ZIP, Zinc importing protein
This table summarizes the list of major zinc transporters involved in supply and homeostasis of zinc in neurons (for 
detail see Ohana et al. 2009)
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structural, and other functional roles have been described. This number is more than that of any other 
transition or Group IIB metal (Vallee and Falchuk 1993) that is involved in biomolecules. Specific 
binding sites for Zn2+ are present on numerous proteins, including Zn2+ fingers on transcription fac-
tors that bind it with high affinity, and metallothioneins, from which the Zn2+ is easily dissociable.
Zinc binds to many proteins involved in gene regulation. The Zn finger proteins as transcription 
factor, Zn twists in steroid receptors, and Zn clusters in the galactose metabolism activator are well 
known examples. Other metalloproteins tightly binding Zn include the RING finger protein family 
(Freemont 1993), the tumour suppressor p53, the human growth hormone-prolactin receptor com-
plex, and metallothionein proteins (Ebadi 1986; Vallee and Falchuk 1993). Zinc also stabilizes the 
3D structure of superoxide dismutase (Salguerio et al. 2007). A partial list of Zn finger transcription 
factors present in different areas and types of cells in the brain is given in Table 149.5. In the brain, 
Zn is structurally important for reelin, a large secreted protein, implicated in the cortical develop-
ment of the mammalian brain. A 2.0-Å crystal structure from the fifth and sixth reelin repeats frag-
ment revealed the presence of Zn2+ bound to them (Yasui et al. 2007).
The biochemical importance of Zn lies in its role as catalytic, coactive (or co-catalytic), structural 
(Vallee and Falchuk 1993; MacDonald 2000), and intracellular signaling factor such as the regulation of 
Table 149.5 Zinc finger transcription factors in the brain
Transcription factor Expression site and/or function
ATBF1   Protein is highly expressed in the midbrain and diencephalon
  mRNA is highly expressed in the brainstem, mostly in embryo and neonatal 
brain, postmitotic neurons in the brainstem
  Expression is transient and weak in the precursor cells at early neurogenesis.
  Expression decreases postnatally, but remains in mature neurons
  Regulation of neuronal cell maturation or region-specific central nervous system 
differentiation
Bcl11A/Evi9/CTIP1  Bcl11A-S/Evi9c is widely expressed in different regions of the rat brain
  Bcl11A-L/Evi9a is expressed in the cerebral cortex, hippocampus, and olfactory 
bulb
DRRF (Sp1 family of 
transcription factors)
 Highly expressed in the neural ectoderm and neural groove
  Moderately expressed in the mesoderm and endoderm at the early embryonic 
stage.
  Highest DRRF mRNA levels in olfactory bulb and tubercle, nucleus accumbens, 
striatum, hippocampus, amygdala, and frontal cortex.
 Regulates dopaminergic neurotransmission
Egr3   Expressed in cortex and colocalized with zif268.
 Important in defining long-term, neuroplastic responses.
FOG-2   Expressed in developing and adult heart, brain, and testis
  Important cofactor for GATA-mediated transcriptional activation in cardiac and 
neural cell lineages.
Ik-1 and Ik-2  Positive regulators of enkephalin gene expression in the developing striatum
  Participate in regulating enkephalinergic differentiation
Lot1   High in cerebellar granule cells, a neuronal population undergoing postnatal 
neurogenesis
MOK2    PAX3 and IRBP (interphotoreceptor retinoid-binding protein) genes are two 
potentially important target genes for the MOK2 protein.
NSM1(IA-1)   In mouse brain, Insm1 is strongly expressed for 2 weeks after birth but shows 
little or no expression thereafter.
  During embryo development Cbl-associated protein may enter the nucleus 
through its own nuclear localization signal or by binding to INSM1.
(continued)
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Table 149.5 (continued)
Transcription factor Expression site and/or function
Plag1, Plag-l2  In the CNS and PNS
 In olfactory and neuroendocrine lineages.
  Might control cell fate and proliferation decisions in the developing nervous 
system (Oncogenes)
REST/NRSF/XBR   Highest levels in the neurons of hippocampus, pons/medulla, and midbrain
  A negative regulator rather than a transcriptional silencer of neuronal gene 
expression and counteracts with positive regulators to modulate target gene 
expression quantitatively in different cell types, including neurons.
RP58   mRNA at E 10 in the neuroepithelium, and subsequently in the VZ of the cerebral 
cortex in the E12 embryo.
  Strong expression in the preplate in the cerebral cortex from this stage onward. 
High levels of expression continue to be detected in the cortical plate and SVZ of 
the neocortex, hippocampus, and parts of the amygdala
Sp8   Expressed in neurogenic regions, which gives rise to olfactory bulb interneurons 
at embryonic and postnatal time points and remains expressed in the calretinin-
expressing and GABAergic/nondopaminergic interneurons of the glomerular 
layer.
  Contributes to olfactory bulb interneuron diversity by regulating the survival, 
migration, and molecular specification of neuroblasts/interneurons.
Wt1  The developing olfactory epithelium
Zac1(Plag family)  Abundantly expressed in many neuroepithelia during early brain development
 Regulates both apoptosis and cell cycle arrest (tumor suppressors)
Zfp423  Expressed within the cerebellum, both in ventricular and external germinal zones.
  Loss of Zfp423 results in diminished proliferation by granule cell precursors in 
the external germinal layer, especially near the midline, and abnormal differentia-
tion and migration of ventricular zone-derived neurons and Bergmann glia
Zic1–5  Precursor cells of the granule neuron and the neurons in cerebellar nuclei
  Neurulation, neuronal differentiation, neural crest specification, the establishment 
of left-right asymmetry, and regulation of cell proliferation
Zif268 (Egr1)  Zif268 is constitutively expressed in several parts including the temporal lobe.
 Zif268 regulates neurological genes and cellular growth and proliferation genes.
  Expressed in mammalian neurons during visual and fear learning, as well as in 
song learning in birds.
  Expressed in response to cellular growth and proliferation signals by enhancing 
the expression of TGF 1
ZNF536   Most abundant in the developing central nervous system and dorsal root ganglia 
and localized in the cerebral cortex, hippocampus, and hypothalamic area.
 Negatively regulates neuron differentiation.
This table includes a partial list of Zn finger transcription factors expressed in different sites and/or cells of the brain. 
Related functions of the respective transcription factors at the expression site are listed as well
cell proliferation (Hershfinkel et al. 2007). The catalytic roles of Zn include participating in the transfor-
mation of substrates by facilitating the formation of OH- at neutral pH, or through Lewis acid catalysis. 
The structural role of Zn is mostly in stabilizing active tertiary peptide conformation. Notably, Zn2+ 
interacts strongly with electronegative sulfur, nitrogen, and oxygen moieties in multiple coordination 
geometries, and yet unlike Fe or Cu, it is not redox active under physiological conditions and thus does 
not promote the formation of toxic free radicals. As an extracellular signal factor Zn is involved in syn-
aptic neurotransmission (Frederickson 1989; Vallee and Falchuk 1993). It is generally accepted that an 
increase in free intracellular Zn2+ is associated with cell death. For example, release of intracellular Zn2+, 
triggered by formation of reactive oxygen species or by nitrosilation, induces proapoptotic molecules, 
e.g., p38, and activation of K+ channels leading to cell death (McLaughlin et al. 2001; Pal et al. 2003).
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149.7  The Developing Brain and Zn Status in Diet
The impact of Zn supplementation or a Zn-deficient human diet on brain development and function 
has not been consistent. Various dimensions of research design and a broad range of subjects varying 
in racial background, age, and food habits might have contributed to the observed inconsistency. 
However, a growing number of studies have shown the influence of maternal Zn on fetal growth and 
development (Goldenberg et al. 1995; Georgieff 2007; Cole and Lifshitz 2008). Daily Zn supple-
mentation in women with relatively low plasma [Zn] in early pregnancy is associated with greater 
infant birth weights and head circumferences, with the effect occurring predominantly in women 
with a body mass index less than 26 kg/m2 (Goldenberg et al. 1995). Very low birth weight of 
Canadian infants scored improved motor development when given Zn supplement (Friel et al. 1993) 
while low birth weight infants in Brazil (Ashworth et al. 1998) and older infants and toddlers in 
Guatemala (Bentley et al. 1997) and India (Sazawal et al. 1996) did not show changes in motor 
development. However, Zn supplementation to Zn-deficient mothers is important for proper brain 
development in neonates (Gibson 1994; Georgieff 2007). An adequate Zn nutriture is essential for 
optimal neurological development (Takeda 2001; Prasad 1997). Additional Zn intake during preg-
nancy results in increased neuronal proliferation in the ventricular zone of the developing brain 
(Azman et al. 2009). Regular consumption of more than the recommended intake, on the other hand, 
can have adverse effects (Ronowska et al. 2007).
149.8  Neurogenesis and Zn Supplement
Neurogenesis is a process to generate postmitoitc neuronal and glial cells from neuroepithelial stem 
cells. Proliferation, cell-cycle arrest, differentiation, migration, and the natural developmental death 
of neural precursors are well coordinated during neurogenesis (Moskowitz and Lo 2003). Optimal 
development of the brain depends on strict co-ordination of these events during neurogenesis. Various 
cell-cycle genes and transcription factors including Zn transcription factors expressed in neurons 
(Table 149.5) govern neurogenesis, which also determines the correct positional identity of the neu-
ral cells from the stem/progenitor cells (Araujo et al. 1990; Edenfeld et al. 2002). In most brain 
regions, the generation and proliferation of neurons is normally restricted to a discrete developmen-
tal period with exceptions for the regions such as hippocampus, dentate gyrus, and the subventricular 
zone (SVZ) of several species (Caviness 1973; Gueneau et al. 1982; Cameron et al. 1993; Kuhn et al. 
1996; Gould et al. 1998; Eriksson et al. 1998; Doetsch et al. 1999), and almost all neurons are gener-
ated before early postnatal life and are generally not replaced with new ones (Rakic 1982). The 
ventricular zone (VZ) is the major site of proliferation and presumably produces all the cell types. A 
second proliferative zone, namely SVZ, also contributes large numbers of neurons to the developing 
cortex (Nowakowski and Rakic 1981). In addition, granule neurons are generated throughout life 
from a population of continuously dividing progenitor cells residing in the subgranular zone of the 
dentate gyrus in the rodent brain (Stanfield and Trice 1988; Kuhn et al. 1996).
In neuronal cells, Zn deficiency induces oxidative stress, alters the normal structure and dynamics 
of the cytoskeleton, affects the modulation of several transcription factors and induces a decreased 
cell proliferation and increased apoptotic death. Thus, Zn deficiency affects critical developmental 
events of neurogenesis (reviewed by Mackenzie et al. 2007; Nakashima and Dyck 2009). Zinc 
supplement on the other hand results in increased number of proliferating neurons in the VZ of the 
developing neocortex. This was observed in the mouse pups delivered by the mother given oral Zn 
supplement in drinking water during pregnancy (Azman et al. 2009). Notably, Zn is involved in 
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activation of enzyme systems that influence cell division and proliferation (Varrault et al. 1998; 
MacDonald 2000; Valente et al. 2005; Ronowska et al. 2007). During DNA synthesis, Zn affects 
thymidine kinase, the activity of which increases dramatically during the G1 and early S phases of 
the cell cycle. Zinc also influences the hormonal regulation of cell division. Insulin-like growth 
factor-I and the pituitary growth hormone axis are responsive to Zn status (Root et al. 1979; Roth 
et al. 1994).
149.9  Neuronal Apoptosis and Zn Deficiency
Zn deficiency was found to increase the expression of Zn transporters in the brain, which facilitates 
increased brain Zn uptake and results in the conservation of brain Zn during Zn deficiency (Chowanadisai 
et al. 2005). In neuronal cells, Zn deficiency induces oxidative stress, alters the normal structure and 
dynamics of the cytoskeleton, affects several transcription factors, and results in decreased cell prolif-
eration and increased apoptosis. These closely associated events affect neuronal function and critical 
developmental events of neurogenesis when Zn availability decreases (Mackenzie et al. 2007).
In human neuronal cell model IMR-32 cells, a decrease in cellular Zn triggers mitogen-activated 




-independent and dependent manner. Cells grown in low 




 release, increased c-Jun N-terminal 
kinase (JNK) and p38 activation, high nuclear activator protein-1 (AP-1)-DNA binding activity, and 




 can trigger the activation of JNK and 
p38, leading to AP-1 activation, events that are not involved in Zn deficiency-induced apoptosis 
(Zago et al. 2005).
149.10  Zinc Deficiency or Excess and Brain Pathology
The homeostasis of the free Zn2+ pool and the mechanisms involved in controlling that homeostasis 
are pivotal for proper brain physiology. Acute human dietary deficiency is accompanied by CNS 
related Zn-reversible symptoms such as anorexia, smell and taste dysfunction, emotional and cogni-
tive disturbances, and loss of coordination (Fig. 149.3) (Ashworth et al. 1998; Bhatnagar and Taneja 
2001). Perhaps this is because Zn as a neuromodulator at excitatory synapses plays an important role 
in stress response and in the functionality of Zn-dependent enzymes contributing to maintaining 
brain compensatory capacity. Dietary Zn deficiency was also reported to affect learning and memory. 
Deficiency in Zn is also associated with attention deficiency/hyperactivity disorder. Age-related 
decline in brain functions and impaired cognitive performances could be related to dysfunctions 
affecting the intracellular Zn2+ availability (Golub et al. 1995; Takeda 2000; Takeda et al. 2008).
Zn deficiency causes abnormal glucocorticoid secretion from the adrenal cortex, which is observed 
prior to the decrease in extracellular [Zn] in the hippocampus. The functions of glucocorticoid recep-
tor-rich hippocampus are changed by abnormal glucocorticoid secretion that in turn aggravates glu-
tamate excitotoxicity in neurological diseases. Thus Zn deficiency elicits neuropsychological 
symptoms and affects cognitive performance (Fig. 149.3). It is possible that the decrease in Zn2+ pool 
in the peripheral tissues triggers abnormal glucocorticoid secretion. In other words, the decrease in 
Zn2+ pool may cooperate with glucocorticoid action in Zn deficiency.
Again, elevated [Zn] or Zn excess in the brain has a profound negative effect on neurological 
cells, which are highly susceptible to extremes in extracellular [Zn]. The exact neuropathological 
mechanism of elevated level of Zn2+ is still unclear; however, it is found to be related to the progression 
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of AD and other neuropathologies (reviewed by Sensi et al. 2009). There is considerable evidence that 
amyloid-beta deposition in AD is induced by Zn, but the exact mechanism is still unclear (reviewd 
by Mocchegiani et al. 2005; Barnham and Bush 2008). An increased expression of MT-I and MT-II, 
and in some cases of MT-III (also known to be a growth inhibitory factor), is causally linked to such 
phenomena (Fig. 149.3). However, the protective roles of these proteins at a young age to maintain 
brain physiology and their functional ability in aging are not consistent. Alterations in Zn homeosta-
sis have also been reported in Parkinson’s disease as well as in transient forebrain ischemia, seizures, 
and traumatic brain injury. The altered Zn nutritional status of individuals with Down’s Syndrome 
contributes to clinical complications that usually appear with their aging (Lima et al. 2010). Again, 
Zn metabolism is altered in the presence of Down’s Syndrome (Licastro et al. 2001). Zinc supple-
ment in diets has been tried to improve the patient’s health albeit with conflicting results (Bucci et al. 
2001; Blair et al. 2008).
149.11  Applications to Other Areas of Health and Disease
The importance of Zn in the biological system is remarkable and versatile. Zinc plays a pivotal role 
in gene expression involving cellular growth and differentiation; yet, unlike other transitional metals, 
Fig. 149.3 Possible pathological consequences of dietary Zn-deficient or Zn-excess condition. In dietary Zn 
deficiency, serum [Zn] can be decreased leading to either increased serum glucocorticoid concentration or decreased 
growth hormone concentration or intracellular [Zn]. These conditions in turn may result in cognitive disturbances such 
as memory or learning impairment, growth retardation or neuronal apoptosis, respectively. In dietary Zn-excess condi-
tion, increased serum [Zn] can lead to decreased uptake of Cu and Fe in different organs, including the brain, or 
increased depositing of beta amyloid in the brain. IGF Insulin like growth factors I, MAPK mitogen activated protein 
kinase,  decrease, increase
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it does not cause any oxidative damage (Berg and Shi 1996). Enough is now known about the clinical 
and public health importance of Zn in human health and diseases. Community Zn supplementation 
programs among children in developing countries proved to have had a significant effect on the 
reduction of pneumonia (Bhutta et al. 1999). Zinc supplement has been beneficial for diarrhea pre-
vention and childhood morbidity and mortality. Other than the brain (CNS), the epidermal, gastroin-
testinal, immune, skeletal, and reproductive systems are known to be affected clinically by severe Zn 
deficiency (Solomons 1998; Hambidge et al. 1986).
 Summary Points
The total Zn content of the diet and its bioavailability, especially its solubility in the intestinal 
lumen, determine the amount of absorbed Zn to be utilized or metabolized in the different organs 
including the brain.
In the brain, Zn concentration is highest in the hippocampus which can decrease significantly in 
dietary Zn deficiency.
The blood brain barrier system provides strict regulation on Zn homeostasis in the brain and is not 
easily influenced by dietary Zn.
Zinc homeostasis is maintained through the regulated expression of proteins for Zn import, export, 
and sequestration.
A multitude of Zn2+ transporters (ZnTs), Zn2+-importing proteins (ZIPs), and buffering proteins 
such as the metallothioneins (MT) bind cytosolic Zn2+ and mediate the complex intraneuronal 
cytosolic free Zn2+ homeostasis.
A number of Zn transcription factors are expressed in nerve cells and in different areas of the 
brain regulating genes involved in proliferation, differentiation, migration, and apoptosis of neu-
rons and other cells of the brain.
As an extracellular signal factor Zn is involved in synaptic neurotransmission.
Additional Zn intake during pregnancy can increase neuronal proliferation at the ventricular zone 
of the developing brain.
In neuronal cells, Zn deficiency induces oxidative stress, alters the normal structure and dynamics 
of the cytoskeleton, affects the modulation of transcription factors AP-1, NF-betaB, and NFAT 
and induces decreased cell proliferation and increased apoptotic death.
Acute human dietary deficiency is accompanied by symptoms such as anorexia, smell and taste 
dysfunction, emotional and cognitive disturbances, and loss of coordination. Dietary Zn defi-
ciency also has been reported to affect brain functions, including learning and memory defects.
Key Terms
Apoptosis: A form of cell death (or cell suicide) in which a programmed sequence of events 
leads to the elimination of cells without leaving or releasing harmful substances into the sur-
rounding area of the dying cell(s). Apoptosis also refers to the structural changes that the cells 
undergo before the programmed death. Apoptosis is crucial in developing and maintaining health 
by eliminating old, unnecessary, and unhealthy cells. Hyperactivation and inactivation of apopto-
sis may result in pathological conditions. Hyperactivation may kill too many cells and inflict 
grave tissue damage, leading to such neurodegenerative disorders as Alzheimer’s, Huntington’s, 
and Parkinson’s diseases.
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Astrocyte: Astrocytes (collectively known as astroglia) are characteristic star-shaped glial cells 
in the CNS. Three forms of astrocytes exist in the CNS: fibrous (located in white matter and that 
physically connect the cells to the outside of the capillary wall when they are in close proximity 
to them), protoplasmic (found in grey matter tissue; they possess a larger quantity of organelles 
and exhibit short and highly branched cellular processes), and radial (disposed in a plane perpen-
dicular to the axis of ventricles). Their functions include: biochemical support to the endothelial 
cells at the BBB, controlling of nutrient supply to the nervous tissue, maintenance of extracellular 
ion balance, and aiding in repair mechanisms of the brain and spinal cord injuries.
Blood brain barrier (BBB): The BBB is a protective network of blood vessels that filters blood 
flowing to the brain and separates circulating blood and cerebrospinal fluid (CSF) maintained by 
the choroid plexus in the CNS. Endothelial cells of the blood vessels restrict the diffusion of 
microscopic objects (e.g. bacteria) and large or hydrophilic molecules into the CSF, while allow-





Central nervous system (CNS): The CNS is one of the two major divisions of the nervous sys-
tem and consists of the brain and the spinal cord. The CNS connects to sensory organs (such as 
the eye and ear) and other organs of the body, muscles, blood vessels, and glands through the 
peripheral nervous system. The CNS consists of the brain in the cranial cavity and the spinal cord 
in the spinal cavity.
Hippocampus: The hippocampus is named for its shape like a seahorse (From the Greek hippos = 
horse and kampos = a sea monster). It is a closely associated, paired structure with mirror-image 
halves in the left and right sides of the brain. In humans and other primates, the hippocampus is 
located inside the medial temporal lobe, beneath the cortical surface. The hippocampus is part of 
the olfactory cortex essential to the sense of smell and also helps to regulate emotion and memory. 
Hippocampus also plays important roles in long-term memory and spatial navigation.
Homeostasis: (from Greek: homoios, “similar”; and hist mi, “standing still”). Generally refers 
to the property of a system, either open or closed, that regulates its internal environment and tends 
to maintain a stable, constant condition. When applied to living organisms, homeostasis refers to 
a property of cells, tissues, and organisms that allow the maintenance and regulation of the stabil-
ity and constancy needed to function properly and is maintained by the constant adjustment of 
biochemical and physiological pathways.
Metallothionein (MT): Metallothionein is a family of cysteine-rich, low molecular weight (3.5–
14 kDa) proteins. The thiol group of MT contains cysteine residues, which represent ~20–30% of 
its total amino acidic residues. Both essential (such as Zn, copper, selenium) and toxic (such as 
cadmium, mercury, silver, arsenic) heavy metals can bind the thiol groups through the cysteine 
residues. MT has high affinity for Zn (1.4 × 10-13 M). There are four major isoforms (MT-I, MT-II, 
MT-III, MT-IV) expressed primarily in the liver and kidneys. MT expression is also evident in 
other tissues and organs such as blood, skin, and heart. In the brain, MT-III is known as the 
growth inhibitory factor. Expression of MT in different organs and tissues depends on the avail-
ability of the dietary minerals, such as Zn, copper, and selenium, and the amino acids histidine and 
cysteine. MT distributes intracellular Zn as Zn undergoes rapid inter- and intracluster exchange.
Neurogenesis: The process by which new nerve cells are generated i.e., production of new neu-
rons, astrocytes, glia, and other neural lineages from undifferentiated neural progenitor or stem 
cells. Neurogenesis is most active during prenatal development and inactive in most areas of the 
adult brain.
Neuron: Neurons are cells in the nervous system including the brain, spinal cord (vertebrate), the 
ventral nerve cord (invertebrate), and the peripheral nerves that process and transmit information by 
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electrochemical signaling. A typical neuron has a cell body (soma), branching processes specialized 
to receive incoming signals (dendrites), and a single process (axon) that carries electrical signals 
away from the neuron toward other neurons or effectors. Electrical signals carried by axons are 
action potentials. Different types of neurons are named after their specialized structure and func-
tions: for example, sensory neurons respond to touch, sound, light, and numerous other stimuli 
affecting cells of the sensory organs that then send signals to the spinal cord and brain; motor 
neurons receive signals from the brain and spinal cord and cause muscle contractions and affect 
glands; interneurons connect neurons to other neurons within the same region of the brain or 
spinal cord.
Dopaminergic neuron: Neurons that produce dopamine, a neurotransmitter produced in several 
areas of the brain, including the substantia nigra and the ventral tegmental area in either verte-
brates or invertebrates. Dopamine is a neurohormone released by the hypothalamus mainly to 
inhibit the release of prolactin from the anterior lobe of the pituitary.
GABAergic neuron: Neurons that produce -aminobutyric acid (GABA), the chief inhibitory 
neurotransmitter in the mammalian CNS. It plays an important role in regulating neuronal 
excitability throughout the nervous system. In humans, GABA is directly responsible for the 
regulation of muscle tone. GABA acts at inhibitory synapses in the brain by binding to specific 
transmembrane receptors in the plasma membrane of both pre- and postsynaptic neuronal pro-
cesses. This binding causes the opening of ion channels to allow the flow of either Cl- ions into 
the cell or K+ out of the cell. Two general classes of GABA receptor are known: GABA
A
 in 
which the receptor is part of a ligand-gated ion channel complex, and GABA
B
 metabotropic 
receptors, which are G protein-coupled receptors that open or close ion channels via 
intermediaries.
Reelin: Reelin is a protein expressed in different tissues of the body including brain, spinal cord, 
and blood. In the developing brain it helps to regulate neuronal migration and positioning. In the 
adult brain, it modulates synaptic plasticity by enhancing the induction and maintenance of long-
term potentiation. It also stimulates dendrite and dendritic spine development and regulates the 
continuing migration of neuroblasts generated in adult neurogenesis sites like subventricular and 
subgranular zones.
Subventricular zone (SVZ): The subventricular zone is a paired brain structure situated 
throughout the lateral walls of the lateral ventricles. Along with the subgranular zone of the 
dentate gyrus, the SVZ serves as a source of neural stem cells in the process of neurogenesis. It 
harbors the largest population of proliferating cells in the adult brain of rodents, monkeys, and 
humans.
Synaptic vesicle: Synaptic vesicles or neurotransmitter vesicles are 40–100 nanometers in 
diameter, and made up of a lipid bilayer, store various neurotransmitters (NT) that are released 
at the synapse for synaptic transmission. The release of NTs is regulated by a voltage-dependent 
Ca+ channel. At synapses, the junctional complexes between presynaptic membranes (synaptic 
knobs) and postsynaptic membranes (receptor surfaces of recipient neurons or effectors), synaptic 
transmission process signal transfer (communicate) from one neuron (affector) to other neurons 
(effectors).
Zinc finger transcription factor: Zinc finger transcription factors are the DNA-binding pro-
teins, containing Zn finger domain. Zinc fingers are small protein domains, folds of which are 
stabilized by one or more Zn2+. They coordinate Zn2+ with a combination of cysteine and histidine 
residues. Different families of Zn finger proteins can bind DNA, RNA, proteins or small mole-
cules involved in transcription, nucleic acid polymerization, and histones.
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